Movement Alert｜10x Genomics, Inc. Rises 5.26% in Regular Trading, Q2 Earnings Beat Expectations and Full-Year Revenue Guidance Raised

Market Focus08-07 23:17

On August 7, 10x Genomics, Inc. rose 5.26% in regular trading, trading at 48.12 USD/share, with turnover of $58.40 million.

On the news front, the company reported Q2 results with a per-share loss of $0.14, significantly better than the analyst consensus estimate of a $0.24 loss, representing a 41.67% beat. Revenue of $151.0 million also exceeded the expected $146.7 million. Additionally, the company raised its full-year revenue guidance to $610 million-$630 million, up from prior guidance of $600 million-$625 million and above the analyst estimate of $613.7 million.

While Q2 revenue declined 12.7% year-over-year from $172.9 million and the company swung to a loss from EPS of $0.28 a year earlier, the substantial earnings beat combined with the upward guidance revision signaled improving fundamentals. After initially declining approximately 5% in after-hours and pre-market sessions following the report, the stock reversed sharply during regular trading as investors digested the positive guidance revision and better-than-expected profitability trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182955519?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 23:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182955519","market":"hk","top_or_hot":-1,"title":"Movement Alert｜10x Genomics, Inc. Rises 5.26% in Regular Trading, Q2 Earnings Beat Expectations and Full-Year Revenue Guidance Raised","media":"Market Focus","content":"<p><p>On August 7, 10x Genomics, Inc. rose 5.26% in regular trading, trading at 48.12 USD/share, with turnover of $58.40 million.</p><p>On the news front, the company reported Q2 results with a per-share loss of $0.14, significantly better than the analyst consensus estimate of a $0.24 loss, representing a 41.67% beat. Revenue of $151.0 million also exceeded the expected $146.7 million. Additionally, the company raised its full-year revenue guidance to $610 million-$630 million, up from prior guidance of $600 million-$625 million and above the analyst estimate of $613.7 million.</p><p>While Q2 revenue declined 12.7% year-over-year from $172.9 million and the company swung to a loss from EPS of $0.28 a year earlier, the substantial earnings beat combined with the upward guidance revision signaled improving fundamentals. After initially declining approximately 5% in after-hours and pre-market sessions following the report, the stock reversed sharply during regular trading as investors digested the positive guidance revision and better-than-expected profitability trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜10x Genomics, Inc. Rises 5.26% in Regular Trading, Q2 Earnings Beat Expectations and Full-Year Revenue Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜10x Genomics, Inc. Rises 5.26% in Regular Trading, Q2 Earnings Beat Expectations and Full-Year Revenue Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 23:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, 10x Genomics, Inc. rose 5.26% in regular trading, trading at 48.12 USD/share, with turnover of $58.40 million.</p><p>On the news front, the company reported Q2 results with a per-share loss of $0.14, significantly better than the analyst consensus estimate of a $0.24 loss, representing a 41.67% beat. Revenue of $151.0 million also exceeded the expected $146.7 million. Additionally, the company raised its full-year revenue guidance to $610 million-$630 million, up from prior guidance of $600 million-$625 million and above the analyst estimate of $613.7 million.</p><p>While Q2 revenue declined 12.7% year-over-year from $172.9 million and the company swung to a loss from EPS of $0.28 a year earlier, the substantial earnings beat combined with the upward guidance revision signaled improving fundamentals. After initially declining approximately 5% in after-hours and pre-market sessions following the report, the stock reversed sharply during regular trading as investors digested the positive guidance revision and better-than-expected profitability trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXG","symbol_name":"10x Genomics, Inc.","start_time":0,"source_url":"","article_id":"1182955519","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182955519","pubTimestamp":1786115865,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, 10x Genomics, Inc. rose 5.26% in regular trading, trading at 48.12 USD/share, with turnover of $58.40 million.On the news front, the company reported Q2 results with a per-share loss of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXG":"10x Genomics, Inc."},"translate_title":"走势警报|10x Genomics, Inc. 常规交易上涨 5.26%，第二季度盈利超出预期，全年收入指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":1},"content_text":"On August 7, 10x Genomics, Inc. rose 5.26% in regular trading, trading at 48.12 USD/share, with turnover of $58.40 million.On the news front, the company reported Q2 results with a per-share loss of $0.14, significantly better than the analyst consensus estimate of a $0.24 loss, representing a 41.67% beat. Revenue of $151.0 million also exceeded the expected $146.7 million. Additionally, the company raised its full-year revenue guidance to $610 million-$630 million, up from prior guidance of $600 million-$625 million and above the analyst estimate of $613.7 million.While Q2 revenue declined 12.7% year-over-year from $172.9 million and the company swung to a loss from EPS of $0.28 a year earlier, the substantial earnings beat combined with the upward guidance revision signaled improving fundamentals. After initially declining approximately 5% in after-hours and pre-market sessions following the report, the stock reversed sharply during regular trading as investors digested the positive guidance revision and better-than-expected profitability trajectory.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182955519","isCrawlerRequest":true}